transferrin has been researched along with Parkinsonian Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberici, A; Albini, E; Alessio, L; Benussi, L; Binetti, G; Bucossi, S; Draicchio, F; Gorgone, G; Lucchini, R; Melgari, JM; Panetta, V; Rossini, PM; Squitti, R | 1 |
| Jiang, H; Qian, ZM; Xie, JX | 1 |
| Li, XB; Liao, GS; Shu, YY; Tang, SX; Zhang, CY | 1 |
3 other study(ies) available for transferrin and Parkinsonian Disorders
| Article | Year |
|---|---|
Implications of metal exposure and liver function in Parkinsonian patients resident in the vicinities of ferroalloy plants.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Copper; Environmental Exposure; Female; Humans; Iron; Italy; Liver; Male; Manganese; Metals, Heavy; Middle Aged; Parkinsonian Disorders; Peroxides; Severity of Illness Index; Time Factors; Transferrin; Zinc | 2009 |
[Increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice].
Topics: Animals; Cation Transport Proteins; Dopamine; Iron; Iron-Binding Proteins; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Protein Isoforms; Substantia Nigra; Transferrin | 2003 |
Pharmacological actions of nerve growth factor-transferrin conjugate on the central nervous system.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Drug Carriers; Injections, Intravenous; Maze Learning; Memory; Mice; Models, Animal; Nerve Growth Factor; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Transferrin | 2001 |